Trials / Completed
CompletedNCT02403986
An Efficacy and Safety Study Evaluating Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face
A Randomised, Multi-centre, Parallel-group, Efficacy and Safety Study Evaluating Two and Three Initial Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- Female
- Age
- 35 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
A randomised, multi-centre, parallel-group efficacy and safety study evaluating two and three initial treatment sessions of Restylane Skinboosters Vital Lidocaine in the face.
Detailed description
Approximately 50 female subjects shall be treated with two or three initial treatment sessions including long-term follow-up 18 months after the initial treatment regimen. Efficacy and safety to be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Restylane Vital Skinboosters Lidocaine |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2017-03-30
- Completion
- 2017-03-30
- First posted
- 2015-03-31
- Last updated
- 2022-08-26
- Results posted
- 2019-09-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02403986. Inclusion in this directory is not an endorsement.